Niels D Prins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5409726/publications.pdf

Version: 2024-02-01

115 papers	7,617 citations	136950 32 h-index	58581 82 g-index
126 all docs	126 docs citations	126 times ranked	9574 citing authors

#	Article	IF	Citations
1	Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline. New England Journal of Medicine, 2003, 348, 1215-1222.	27.0	2,037
2	White matter hyperintensities, cognitive impairment and dementia: an update. Nature Reviews Neurology, 2015, 11, 157-165.	10.1	811
3	Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain, 2005, 128, 2034-2041.	7.6	646
4	Progression of Cerebral Small Vessel Disease in Relation to Risk Factors and Cognitive Consequences. Stroke, 2008, 39, 2712-2719.	2.0	492
5	Cerebral White Matter Lesions and the Risk of Dementia. Archives of Neurology, 2004, 61, 1531.	4.5	441
6	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	2.6	307
7	Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan Study. Brain, 2006, 129, 182-188.	7.6	203
8	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
9	Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia. Stroke, 2003, 34, 1907-1912.	2.0	158
10	Plasma amyloid Î², apolipoprotein E, lacunar infarcts, and white matter lesions. Annals of Neurology, 2004, 55, 570-575.	5.3	112
11	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.	4.5	99
12	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 531-540.	0.8	99
13	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimerâ€™s disease. European Radiology, 2017, 27, 1169-1175.	4.5	97
14	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.1	97
15	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	6.2	87
16	Alcohol intake in relation to brain magnetic resonance imaging findings in older persons without dementia. American Journal of Clinical Nutrition, 2004, 80, 992-997.	4.7	86
17	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimerâ€™s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research and Therapy, 2018, 10, 107.	6.2	80
18	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke, 2015, 46, 2661-2664.	2.0	73

#	Article	IF	Citations
19	Prevalence of cortical superficial siderosis in a memory clinic population. Neurology, 2014, 82, 698-704.	1.1	71
20	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2488-2494.	3.1	66
21	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. Frontiers in Aging Neuroscience, 2018, 10, 279.	3.4	61
22	Cerebral small vessel disease affects white matter microstructure in mild cognitive impairment. Human Brain Mapping, 2014, 35, 2836-2851.	3.6	59
23	Diagnostic impact of CSF biomarkers for Alzheimer's disease inÂaÂtertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.8	59
24	Treating Alzheimerâ€™s disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research and Therapy, 2013, 5, 56.	6.2	51
25	Microbleeds, Mortality, and Stroke in Alzheimer Disease. JAMA Neurology, 2015, 72, 539.	9.0	48
26	An exploratory clinical study of p38Î± kinase inhibition in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2018, 5, 464-473.	3.7	43
27	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiology of Aging, 2019, 84, 225-234.	3.1	42
28	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.1	41
29	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping, 2018, 39, 3143-3151.	3.6	40
30	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using twoâ€dimensional phaseâ€contrast magnetic resonance imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 76-83.	2.4	39
31	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. Scientific Reports, 2019, 9, 16742.	3.3	38
32	Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. Alzheimer's and Dementia, 2022, 18, 810-823.	0.8	38
33	Amyloid-Î² Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience, 2019, 11, 7.	3.4	37
34	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 106.	6.2	37
35	The influence of cerebral small vessel disease on default mode network deactivation in mild cognitive impairment. NeuroImage: Clinical, 2013, 2, 33-42.	2.7	36
36	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics DespiteÂMultidisciplinary Application ofÂtheÂFTDC Criteria. Journal of Alzheimer's Disease, 2017, 60, 959-975.	2.6	34

#	Article	IF	Citations
37	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2020, 89, 99-107.	3.1	34
38	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatricÂdisorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 99-106.	2.4	32
39	Glucocorticoid receptor variant and risk of dementia and white matter lesions. Neurobiology of Aging, 2008, 29, 716-723.	3.1	30
40	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	1.2	30
41	Personalized risk for clinical progression in cognitively normal subjectsâ€"the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
42	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dementia and Geriatric Cognitive Disorders, 2016, 41, 210-219.	1.5	29
43	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the â€œUtrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairmentâ€•(TRACE-VCI) Study. JMIR Research Protocols, 2017, 6, e60.	1.0	29
44	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2665-2670.	3.1	28
45	The effect of hippocampal function, volume and connectivity on posterior cingulate cortex functioning during episodic memory fMRI in mild cognitive impairment. European Radiology, 2017, 27, 3716-3724.	4.5	28
46	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. American Journal of Geriatric Psychiatry, 2015, 23, 1056-1066.	1.2	26
47	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. Neurology, 2019, 92, e1558-e1566.	1.1	24
48	Amyloid imaging in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 26.	6.2	23
49	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	3.6	23
50	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia, 2019, 131, 184-192.	1.6	22
51	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 169-178.	2.6	21
52	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. Journal of Alzheimer's Disease, 2013, 36, 79-85.	2.6	21
53	Can novel therapeutics halt the amyloid cascade?. Alzheimer's Research and Therapy, 2010, 2, 5.	6.2	19
54	Amyloid imaging in clinical trials. Alzheimer's Research and Therapy, 2013, 5, 36.	6.2	18

#	Article	IF	Citations
55	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. Journal of Alzheimer's Disease, 2017, 56, 249-259.	2.6	18
56	The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome. Journal of Clinical Psychiatry, 2017, 78, e1197-e1203.	2.2	18
57	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2019, 68, 311-322.	2.6	16
58	Design of the ExCersionâ€VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 157-165.	3.7	15
59	Plasma Î² amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiology of Aging, 2007, 28, 707-712.	3.1	12
60	Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2016, 51, 1249-1256.	2.6	12
61	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase, 2016, 22, 285-288.	0.6	12
62	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
63	Episodic Memory Impairment in Frontotemporal Dementia; A ^{99m}Tc- HMPAO SPECT Study. Current Alzheimer Research, 2013, 10, 332-339.	1.4	11
64	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. Nutrients, 2019, 11, 1057.	4.1	10
65	Methylphenidate and galantamine in patients with vascular cognitive impairmentâ€“the proof-of-principle study STREAM-VCI. Alzheimer's Research and Therapy, 2020, 12, 10.	6.2	10
66	Serum proteomics in amnestic mild cognitive impairment. Proteomics, 2013, 13, 2526-2533.	2.2	9
67	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesionâ€“symptom mapping study. Journal of Psychiatry and Neuroscience, 2019, 44, E1-E10.	2.4	9
68	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. Journal of Alzheimer's Disease, 2021, 82, 381-390.	2.6	8
69	Microbleeds are associated with depressive symptoms in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 112-120.	2.4	7
70	Neuropathology of FMR1-premutation carriers presenting with dementia and neuropsychiatric symptoms. Brain Communications, 2021, 3, fcab007.	3.3	7
71	Comorbid amyloidâ€Î² pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 2020, 16, 354-364.	0.8	6
72	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2021, 108, 146-154.	3.1	6

#	Article	IF	Citations
73	Subjective cognitive decline and selfâ€reported sleep problems: The SCIENCe project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	5
74	MRI and CSF biomarkers in ADâ€"accuracy and temporal change. Nature Reviews Neurology, 2010, 6, 650-651.	10.1	4
75	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. Journal of Alzheimer's Disease, 2019, 68, 1273-1286.	2.6	4
76	[P2â€"052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P624.	0.8	3
77	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Research Protocols, 2018, 7, e80.	1.0	3
78	Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race. Alzheimer's and Dementia, 2022, 18, 867-868.	0.8	3
79	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100141.	0.9	2
80	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
81	P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.	0.8	1
82	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project. Alzheimer's and Dementia, 2020, 16, e044783.	0.8	1
83	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, , .	1.2	1
84	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
85	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
86	P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P806-P806.		0
87	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
88	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
89	P2â€221: Cerebral Blood Flow Measured with Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P706.	0.8	0
90	ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.8	0

#	Article	IF	Citations
91	P4-159: Screening and Recruitment Experience When Using Biomarker-Based Population Definition in Alzheimerâ€™s Disease Studies. , 2016, 12, P1075-P1076.		0
92	[P3â€“422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. Alzheimer's and Dementia, 2017, 13, P1127.	0.8	0
93	[ICâ€Pâ€095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P74.	0.8	0
94	[ICâ€Pâ€110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.8	0
95	[P2â€“211]: AMYLOIDâ€Î²42 (AÎ²42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOIDâ€POSITIVE VERSUS AMYLOIDâ€NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC ATâ€RISK FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.	0.8	0
96	[O1â€“01â€“02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P182.	0.8	0
97	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.8	0
98	[O2â€“09â€“06]: EVIDENCE THAT ORAL P38 MAPK ALPHA ANTAGONISM IMPROVES EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER's DISEASE (AD). Alzheimer's and Dementia, 2017, 13, P576.	0.8	0
99	O1â€14â€04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESIONâ€SYMPTOM MAPPING STUDY. Alzheimer's and Dementia, 2018, 14, P259.	0.8	0
100	ICâ€Pâ€111: [¹⁸F]FLORBETAPIRâ€SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P95.	0.8	0
101	P1â€357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNGâ€ONSET DEMENTIA. Alzheimer's and Dementia, 2018, 14, P431.	0.8	0
102	P1â€016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.8	0
103	O2â€06â€03: AMYLOIDâ€Î² LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P632.	0.8	0
104	O2â€06â€01: [¹⁸F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P630.	0.8	0
105	O2â€14â€04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATEâ€ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. Alzheimer's and Dementia, 2018, 14, P657.	0.8	0
106	P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. Alzheimer's and Dementia, 2018, 14, P1366.	0.8	0
107	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1394.	0.8	0
108	Dutch Brain Research Registry for online study participant recruitment: Design and first results. Alzheimer's and Dementia, 2020, 16, e044738.	0.8	0

#	Article	IF	Citations
109	Neuropathology of FMR1â€premutation carriers presenting with dementia and neuropsychiatric symptoms. Alzheimer's and Dementia, 2020, 16, e044916.	0.8	0
110	Grey zone amyloid burden heralds future memory decline: The SCIENCe Project. Alzheimer's and Dementia, 2020, 16, e045210.	0.8	0
111	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.9	0
112	Can we improve clinical trial design in Alzheimerâ€™s disease? The participants point of view. Alzheimer's and Dementia, 2021, 17, .	0.8	0
113	Neuropsychiatric symptoms in patients with possible vascular cognitive impairment: Does sex matter?. Alzheimer's and Dementia, 2021, 17, .	0.8	0
114	Subjective cognitive decline and selfâ€reported sleep at a memory clinic: The SCIENCe project. Alzheimer's and Dementia, 2021, 17, .	0.8	0
115	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. Alzheimer's and Dementia, 2021, 17, .	0.8	0